SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported) May 5, 2005
BARR PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
| | | | | |
| Delaware | | 1-9860 | | 42-1612474 |
(state or other jurisdiction
of incorporation) | | (Commission
File Number) | | (IRS Employer
Identification No.) |
| | | | | |
400 Chestnut Ridge Road, Woodcliff Lake, NJ
| | 07677-7668 |
(Address of principal executive offices)
| | (Zip code) |
(201) 930-3300
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| | | |
| o | | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| | | |
| o | | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| | | |
| o | | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240-14d-2(b)) |
| | | |
| o | | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
TABLE OF CONTENTS
Item 2.02 Results of Operations and Financial Condition.
On May 5, 2005, Barr Pharmaceuticals, Inc. (the “Company”) issued a press release announcing results for the three and nine months ended March 31, 2005. A copy of the release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The Company scheduled a conference call and webcast at 8:30AM Eastern time on Thursday, May 5, 2005 to discuss the results. A replay of the conference call will be available from 12 Noon Eastern time on May 5th through 11:59PM Eastern time on May 8th,and can be accessed by dialing (800) 475-6701 in the United States or (320) 365-3844 Internationally and using access code 779489. A replay of the call is available on the Company’s website at www.barrlabs.com in the Investor Relations/Audio Archives section.
Item 9.01 Financial Statements and Exhibits.
(c)Exhibits
The following Exhibit is being furnished as part of this Current Report on Form 8-K:
| | | |
| Exhibit Number | | Exhibit |
| 99.1 | | Barr Pharmaceuticals, Inc. May 5, 2005 earnings release. |
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | |
| | BARR PHARMACEUTICALS, INC. | | |
| | | | |
| Date: May 5, 2005 | | /s/ William T. McKee | | |
| | | | |
| | William T. McKee | | |
| | | Vice President, Chief Financial Officer, and Treasurer |
